Payment overview · 2025
General Payments
$21,402.30
61 reported records · 13 companies
Healthcare provider profile · identity verified
Michael David Patterson, D.O.
Allopathic & Osteopathic Physicians|Ophthalmology · CROSSVILLE, TN · NPI 1851654867
Verified facts
What the public records show
CMS Open Payments records show Michael David Patterson, D.O. received $21,402.30 in general payments during 2025 across 61 reported records.
Bausch & Lomb Americas Inc. accounted for 63.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lumigan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xiidra by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $13,499.93 | 63.1% | 17 | 2025 |
| NEW WORLD MEDICAL,INC. | Unresolved — no canonical attribution shown | $2,700.00 | 12.6% | 3 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $2,531.19 | 11.8% | 7 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $1,927.10 | 9.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.97 | 1.1% | 12 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $179.00 | 0.8% | 6 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $134.37 | 0.6% | 5 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $52.81 | 0.2% | 2 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $43.17 | 0.2% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.98 | 0.1% | 1 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $29.27 | 0.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.25 | 0.1% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $22.26 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $18,150.00 | 14 |
| Food and Beverage | $1,752.30 | 46 |
| Honoraria | $1,500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $9,915.60 | 8 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $3,150.00 | 4 | 2025 |
Source payment records
|
|||||
| Crystalens Accommodating IOL (AT-52AO) Normalized: crystalens accommodating iol at 52ao |
Device | Bausch & Lomb Americas Inc. | $2,800.00 | 1 | 2025 |
Source payment records
|
|||||
| Ahmed Glaucoma Valve Normalized: ahmed glaucoma valve |
Device | NEW WORLD MEDICAL,INC. | $2,700.00 | 3 | 2025 |
Source payment records
|
|||||
| Clearpath Normalized: clearpath |
Device | NEW WORLD MEDICAL,INC. | $2,700.00 | 3 | 2025 |
Source payment records
|
|||||
| Kahook Dual Blade Normalized: kahook dual blade |
Device | NEW WORLD MEDICAL,INC. | $2,700.00 | 3 | 2025 |
Source payment records
|
|||||
| Streamline Normalized: streamline |
Device | NEW WORLD MEDICAL,INC. | $2,700.00 | 3 | 2025 |
Source payment records
|
|||||
| Via360 Normalized: via360 |
Device | NEW WORLD MEDICAL,INC. | $2,700.00 | 3 | 2025 |
Source payment records
|
|||||
| Travoprost Intraocular Implant - iDose Normalized: travoprost intraocular implant idose |
Drug | Glaukos Corporation | $2,125.00 | 2 | 2025 |
Source payment records
|
|||||
| Compact Intuitiv Normalized: compact intuitiv |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,875.00 | 3 | 2025 |
Source payment records
|
|||||
| IFS ADVANCED FEMTOSEC LASER Normalized: ifs advanced femtosec laser |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,875.00 | 3 | 2025 |
Source payment records
|
|||||
| INTRALASE FS FEMTOSEC LASER Normalized: intralase fs femtosec laser |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,875.00 | 3 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $249.32 | 3 | 2025 |
Source payment records
|
|||||
| Vabysmo Normalized: vabysmo |
Drug | Genentech USA, Inc. | $179.00 | 6 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $134.37 | 5 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $112.44 | 6 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $90.10 | 4 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $52.10 | 1 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $43.17 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| STELLARIS Normalized: stellaris |
Device | Bausch & Lomb Americas Inc. | $26.76 | 1 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $25.43 | 2 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma US Inc | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| ScoutPro Osmolarity System Normalized: scoutpro osmolarity system |
Device | Bausch & Lomb Americas Inc. | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| enVista Aspire Toric IOL Normalized: envista aspire toric iol |
Device | Bausch & Lomb Americas Inc. | $20.27 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Latanoprost | Latanoprost | 558 | 173 |
| Prednisolone Acetate | Prednisolone Acetate | 335 | 218 |
| Erythromycin | Erythromycin Base | 240 | 222 |
| Prednisone | Prednisone | 198 | 197 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 174 | 174 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 172 | 55 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 135 | 122 |
| Fluorometholone | Fluorometholone | 126 | 56 |
| Timolol Maleate | Timolol Maleate | 125 | 41 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 66 | 41 |
| Restasis | Cyclosporine | 53 | 24 |
| Azithromycin | Azithromycin | 52 | 45 |
| Brimonidine Tartrate | Brimonidine Tartrate | 49 | 23 |
| Ofloxacin | Ofloxacin | 42 | 36 |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 24 |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,402.30 · 61 records | Bausch & Lomb Americas Inc. | Ahmed Glaucoma Valve, Cequa, Clareon PanOptix Pro, Clearpath, Compact Intuitiv, Crystalens Accommodating IOL (AT-52AO), DURYSTA, EYLEA HD, IFS ADVANCED FEMTOSEC LASER, IHEEZO, INTRALASE FS FEMTOSEC LASER, Izervay, Kahook Dual Blade, LUMIGAN, OXERVATE, Photrexa Viscous and Photrexa, STELLARIS, ScoutPro Osmolarity System, Streamline, Syfovre, Tecnis Simplicity, Travoprost Intraocular Implant - iDose, VEVYE, Vabysmo, Via360, XEN GLAUCOMA TREATMENT SYSTEM, enVista Aspire Toric IOL, enVista Envy IOL, enVista MX60 IOL, iDoseTR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lumigan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error